SMi Group's Pharmaceutical Microbiology UK 2020 conference takes place in London in January

1. CHAIRS FOR 2020:
• James Drinkwater, Chairman, Pharmaceutical and
Healthcare Science Society
• Olivier Chancel, Sterility and Aseptic Practices Expert,
boehringer ingelheim
FEATURED 2020 SPEAKERS iNClUDE:
• luis Meirinhos-Soares, GMP Inspector, infarmed iP
• Tim Eaton, Sterile Manufacturing Specialist,
AstraZeneca
• Pratixa Patel, Senior Director, Microbiology and
Stability Sciences, gSK
• ian Symonds, Pharmaceutical Consultant, SDA Pharma
• Michael Song, Senior Manager, Medimmune
• Maria Jose Zafra-Domene, Microbiology QC Team
Leader, MeiragTx
• ingo Spreitzer, Deputy Head Section Microbial Safety,
Paul Ehrlich institut
• Jim Polarine, Senior Technical Service Manager, STERIS
Corporation
HigHligHTS FOR 2020:
• Discuss the regulatory expectations and supportive
guidance on bio-contamination control and monitoring in
aseptic manufacturing of sterile products from PHSS
• gain valuable insight from key opinion leaders in a panel
discussion on the impact of the Annex 1 revisions on
pharmaceutical microbiology
• Examine the common myths and urban legends in the
pharmaceutical industry related to contamination control
from STERIS
• Explore container closure integrity and controls strategies
ensuring product sterility from AstraZeneca
• Revisit the role of the Offi cial Medicines Control
Laboratories as the GMP back up from infarmed iP
CONFERENCE: 20TH-21ST
WORKSHOP DAY: 22ND
JAN
2020
COPTHORNE TARA HOTEl, lONDON, UK
SMi group Proudly Presents The 9th Annual...
Discovering optimised contamination control
and the current regulatory landscape
Pharmaceutical
Microbiology UK
www.pharma-microbiology.com
Register online or fax your registration to +44 (0) 870 9090 712
or call +44 (0) 870 9090 711
SMi Pharma
@SMi Pharma
#SMiPharmaMicroUK
bOOK bY 30TH SEPTEMbER AND SAvE £400
bOOK bY 31ST OCTObER AND SAvE £200
bOOK bY 29TH NOvEMbER AND SAvE £100
PlUS iNTERACTivE POST-CONFERENCE WORKSHOP DAY | WEDNESDAY 22ND JANUARY 2020, COPTHORNE TARA HOTEl, lONDON, UK
A: How to Develop a Risk based Approach to
Cleaning and Disinfection
Jim Polarine, Senior Technical Service Manager,
STERiS Corporation
08.30 – 11.40
b: Designing an Environmental
Monitoring Programme
ian Symonds, Director/Pharmaceutical
Consultant, SDA Pharma
12.40 - 15.40
C: Rapid Micro Methods, Endotoxin Testing and lER
Felix Alejandro Montero Julian, Scientifi c Director, bioMerieux
Stefane Schweicher, Business Development Manager Endotoxin
NEC, bioMerieux
15.40 - 18.40
SPONSORED bY:

2. Pharmaceutical Microbiology UK
CONFERENCE DAY ONE | Monday 20th January 2020 www.pharma-microbiology.com
Register online at www.pharma-microbiology.com
lETTER FROM THE CHAiRS:
Dear Colleagues,
As chair of SMi’s 2020 Pharmaceutical Microbiology UK Conference
and on behalf of SMi Group, I am delighted to cordially invite you to our
conference and workshop day.
At the very core of pharmaceutical microbiology is the accurate and
reliable detection of microorganisms that would otherwise contaminate
the pharmaceutical products manufactured. This demand for more
rapid methods for detection and identifi cation will be accompanied by
equally important areas such as: contamination control strategies and
environmental monitoring, process automation, and discussing updates to
meet regulatory requirements.
This year’s conference will explore guidance and regulation including
the regulatory expectations on bio-contamination control and insights
into the impact of Annex 1 revisions on sterile pharmaceutical product
manufacturing. Furthermore, there will be an exploration into microbial
detection as well as environmental monitoring and contamination controls.
This year’s agenda will also assess novel and emerging therapies of the
biopharmaceutical industry and ATMP community assessing the key
developments in the fi eld. The pharmaceutical microbiology workshop
day will discuss how to develop risk based approaches to cleaning and
disinfection, designing an environmental monitoring programme and
rapid micro methods, endotoxin testing and LER through three insightful
interactive workshops.
We hope you can join us to explore novel and developing technologies
that tackle the most pressing challenges and push innovation in the world
of pharmaceutical microbiology.
Kind regards
Olivier Chancel, James Drinkwater,
Sterility and Aseptic Chairman,
Practices Expert, Pharmaceutical and
boehringer ingelheim Healthcare Science Society
8.30 Registration & Coffee
9.00 Chair’s Opening Remarks
Olivier Chancel, Sterility and Aseptic Practices Expert, boehringer
ingelheim
gUiDANCE AND REgUlATiON
KEYNOTE PRESENTATiON
9.10 Regulatory expectations and supportive guidance on
bio-contamination control and monitoring in Aseptic
manufacturing of sterile products
• Regulatory requirements e.g. Annex 1, 2, Regulatory expectations
e.g. Q&A, Blogs, supportive GMP Guidance e.g. PHSS, BioPhorum
(BPOG) – how they relate and current harmonization initiatives
• Preparation of a Contamination Control Strategy (CCS) – an
Annex 1 requirement and Considerations in preparation of an
Aseptic-Containment Strategy (ACS) if toxic or biologically active
products are aseptically processed and/or cross contamination
control is required
• Risk based rationale and supporting risk assessments to setting
environmental monitoring locations and sampling frequencies –
PHSS and BPOG collaboration initiative
James Drinkwater, Chairman, Pharmaceutical and Healthcare
Science Society
9.50 Annex 1 Revision
• History of Annex 1
• Current Annex 1 key elements
• Early indicators of the changes expected in Annex 1
• Industry comments regarding the draft published in 2017
• Where now for Annex 1?
ian Symonds, Director, Pharmaceutical Consultant, SDA Pharma
10.30 The Role of the Official Medicines Control laboratories as the gMP
back-up
• What is and What is not an Offi cial Medicines Control Laboratory (OMCL)
• The role of OMCLs as the analytical hands-on support to GMP
Inspections
• Pre-market and Post-market activities of OMCLs
• Examples of Good, Not-So-Good and Bad Practices as seen from
the authorities perspective
luis Meirinhos-Soares, GMP Inspector, infarmed iP
11.10 Morning Coffee
PANEl DiSCUSSiON
11.40 The impact of the Annex 1 Revision on Pharmaceutical
Microbiology
• Which RMM technologies are being used without regulatory
confl ict on microbiological sampling results - Is industry ready for
integration of digital platforms?
• The removal of contamination risk from operators through use of
gloveless cells and robotics in fi lling platforms
• What does the unity of environmental classifi cation, qualifi cation
and process monitoring mean to EM programs and data
management of total particulate and microbiological samples?
• How do we manage risks associated with aseptic manufacturing
of toxic and biologically hazardous products such as EM sample
contamination, product cross contamination and personnel exposure?
• Assessing the disinfection rotation section on the use of multiple
disinfectants to prevent the development of resistant strains – is
there enough evidence?
• Revisiting the potential latent risk of VBNC and stressed microbial
contamination in sterile product manufacturing
Moderator: Olivier Chancel, Sterility and Aseptic Practices Expert,
boehringer ingelheim
Panellists:
James Drinkwater, Chairman, Pharmaceutical and Healthcare
Science Society
ian Symonds, Director, Pharmaceutical Consultant, SDA Pharma
luis Meirinhos-Soares, GMP Inspector, infarmed iP
Tim Eaton, Sterile Manufacturing Specialist, AstraZeneca
Jim Polarine, Senior Technical Service Manager, STERiS Corporation
MiCRObiAl DETECTiON AND iDENTiFiCATiON
12.40 New At-line Automated Mycoplasma Testing: A Performance
Evaluation of bioFire Mycoplasma
• Current methods description
• New technology: how it works? What are the benefi ts?
• Internal validation data according to Pharmacopeia guidelines
Sylvanie Cassard guilloux, Global Solution Manager,
bioMerieux
13.20 Networking lunch
14.20 Current status of the MAT and rFc
• Foreseen modifi cation of MAT 2.6.30.
• Feedback on draft rFc 2.6.32.
• European and global situation of MAT and rFc
ingo Spreitzer, Deputy Head Section Microbial Safety,
Paul Ehrlich institut
ENviRONMENTAl MONiTORiNg AND CONTAMiNATiON CONTROl
15.00 Automation for incubation and colony counting of Environmental
Monitoring samples: process optimization and data integrity
• Flexible, customizable and fully-automatic equipment for
incubation and colony counting of environmental monitoring
samples in pharmaceutical production
• Quality standardization, process digitalization and data integrity
throughout the daily workfl ow, with full connectivity with the
existing LIMS platform
• FLOQSwabs: a new philosophy for sample collection
• The critical issues in the collection of the environmental sample
• Improve effi ciency in evaluation of environmental microbial
contamination in pharma sector
Sonia Allibardi, Market Access Manager, Copan group
gabriele Savoldi, Business Development Manager,
Copan group
15.40 Afternoon Tea
ASTRAZENECA SPOTligHT PRESENTATiON
16.10 Effective Risk Management of Microbial Contamination
• Risk assessment methods for microbial contamination
• Quantifi cation of microbial contamination using
environmental monitoring data
• Meaningful cleanroom environmental monitoring and Annex 1
considerations
• Effective risk based monitoring locations utilising appropriate risk
factors
Tim Eaton, Sterile Manufacturing Specialist, AstraZeneca
16.50 Microbial Control Considerations for Tablet Manufacture
• Overview of microbial control strategy of the manufacture of oral
solid dosage forms
• Summary of three laboratory based challenge studies
- Growth potential of microorganisms in coating suspensions
- Behavior of microorganisms in tablet coating processes
- Survival of microbes in wet granulation processes
• Application of Water Activity for risk-based testing plans
Sophie Drinkwater, QC Technical Offi cer, AstraZeneca
17.30 Chair’s Closing Remarks and Close of Day One

3. Pharmaceutical Microbiology UK
CONFERENCE DAY TWO | Tuesday 21st January 2020 www.pharma-microbiology.com
Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
8.30 Registration & Coffee
9.00 Chair’s Opening Remarks
James Drinkwater, Chairman, Pharmaceutical and Healthcare
Science Society
Environmental Monitoring and Contamination ConTROL
KEYNOTE PRESENTATION
9.10 Container Closure Integrity and Controls Strategies
Ensuring Product Sterility
• Explore and learn when the utilize the different container closure
integrity (deterministic and probabilistic) test methods mentioned
in FDA guidance and USP <1207>
• New technologies with increased sensitivity…what is a good
detection limit to target and when to draw the line
• How and when to utilize microbial challenge to help set
manufacturing parameters
• Holistic approach in defining your container closure integrity
controls strategy and aseptic assurance
Michael Song, Senior Manager, AstraZeneca
SPOTLIGHT PRESENTATION
9.50 Common Myths and Urban Legends in the
Pharmaceutical Industry Related to Contamination Control
• Disinfectant Quantity – The misconception that more disinfecting
agent is always better for sanitization of surfaces
• Microbiological Resistance – The misconception that micro-
organisms will develop resistance over time to the use of
disinfectants
• Disinfection Rotation – The misconception that disinfection rotation
is required to prevent microbiological resistance (i.e., Myth #1)
• Effectiveness of Isopropyl Alcohol­ – The misconception that
70% Isopropyl Alcohol (IPA) is effective for control of fungal and
bacterial spores
Jim Polarine, Senior Technical Service Manager, STERIS Corporation
10.30 Morning Coffee
11.00 Online Microbial Monitoring for Process Control of Pharmaceutical
Waters
• Current state of real time microbial detection technology
• Case studies for the implementation of online microbial monitoring
at pharmaceutical facilities
• Guidance for evaluation and establishment of new microbial limits
• The Pharmacopeia and Regulatory positions on validation of
alternative microbial methods
James Cannon, Head of OEM and Markets,
Mettler Toledo
11.40 Commissioning of a brand-new cleanroom facility from the
environmental monitoring perspective
• The challenges of commissioning a brand-new facility
• Risk assessment of the cleanroom and the processes
• Establishing a routine Environmental Monitoring programme
Maria Jose Zafra-Domene, Microbiology QC Team Leader, MeiraGTx
Microbial Detection and Identification
12.20 Bacterial Endotoxins Test – Why are my CVs so high?
• What is correlation of variation and how to apply it in BET
• What causes high CVs in BET
• How to identify the root of high CVs
• How to mitigate high CVs
Veronika Wills, Manager, Technical Services,
Associates of Cape Cod International
13.00 Networking Lunch
GSK SPOTLIGHT SESSION
14.00 Aseptic Audit Observations
• What auditor/inspector expectations are
• What audit finding classifications can be used
• Examples of audit observations
• Keeping up to date
Di Morris, Audit Manager CAG, GSK
14.40 Microbial Robustness in Product Design
• Impact of product design on manufacturing
• Going beyond Pharmacopeia Requirements
• Assessing the effectiveness of Microbial controls
Pratixa Patel, Senior Director, Microbiological and Stability Sciences,
GSK
15.20 Afternoon Tea
NOVEL AND EMERGING THERAPIES
15.50 Importance of Microbiological Standards for Personalized Medicines
and Compounding
• Review of current trends and practices in EU and US
• Implementation of technological advancements and other best
practices
• Review of new guidances, guidelines, and regulatory
enforcement activities
• A look into the future of global personalized medicine
Jason McGuire, VP, Quality and Regulatory, Fagron
16.30 Microbial Risk Assessment for Non-Sterile Oral Dosage Forms
• Problem statement
• Risk Assessments
• Control strategy
• Objectionable organisms
• Conclusions
David Elder, Principal Consultant, David P Elder Consultancy
17.10 Chair’s Closing Remarks and Close of Day Two
Engage with top microbiologists in our
microbiology focused conference
Hear from 20+ presentations on the contamination
control and environmental monitoring
Network with industry pharma leaders
in the exhibition area

4. Register online at www.pharma-microbiology.com
b: Designing an Environmental Monitoring Programme 12.40 - 15.40
Workshop leader:
ian Symonds, Director/Pharmaceutical Consultant, SDA Pharma
Workshop overview:
Environmental monitoring has a very limited capability of providing assurance of good hygiene control, therefore it must be optimised, based upon a risk
assessment. The workshop will provide information regarding the contamination challenges from the environment, operators, equipment failure and design
limitations. In addition, the workshop will discuss the monitoring techniques and instruments used to generate the data and will involve some practical exercises.
At the end of the workshop, the delegates will have a clear understanding of the limitations and strengths of environmental monitoring and how to design and
execute the monitoring programme.
About the Workshop leader:
Recently established SDA Pharma Limited with co-managing Director Mike Davies. With almost 80 years’ experience in the industry SDA can provide
a wide range of services form facility design and Qualifi cation support to bespoke training and regulatory compliance advice. Having previously
worked at GSK Global Quality, Ian was responsible for setting and monitoring Quality standards for the Global Manufacture and Supply division for
pharmaceutical sterile manufacturing operations worldwide. Following the merger of GlaxoWellcome and SmithKlineBeecham in 2000, he established
a team of subject matter experts to establish a common set of compliance standards for the new GSKs Quality Management System. Ian continued to
lead that team right up to his retirement in 2018. As a leading Company Subject Matter Expert, regarding the manufacture of sterile parenteral products,
Ian leads an expert team in carrying out Due Diligence evaluation, internally and externally focusing on facility, equipment and capability. These activities took
him to all parts of the world including Russia, China, South America, USA , India, Africa and many other locations. In 2017, he was awarded the honour of Senior
Fellow GSK. External professional involvement includes membership of the Pharmaceutical Healthcare Sciences Society (PHSS) where he is an active member of
the Biocontamination Control Interest Group.
A: How to Develop a Risk based Approach to Cleaning and Disinfection 8.30 - 12.30
Workshop leader:
Jim Polarine, Senior Technical Service Manager, STERiS Corporation
Workshop overview:
This workshop will cover the current industry trends and best practices in disinfectant global regulations,
rotation, disinfectant application methods, application frequencies, residue removal and rinsing
strategies, disinfectant validation and a case study in bioburden control will be covered. CAPA
investigations related to contamination control in cleanroom operations will be covered. Annex I (Draft
2018), FDA Warning Letters, FDA 483s, and PDA Technical Report No. 70 sections will be covered which
relate to the topics mentioned. The workshop will focus on industry trends and industry best practices
based on 20 years of global industry experiences.
About the Workshop leader:
Mr. Polarine is a senior technical service manager at STERIS Corporation. He has been
with STERIS Corporation for eighteen years. His current technical focus is microbial
control in cleanrooms and other critical environments. Mr. Polarine is a 2019 PDA
Michael S. Korczynski Award recipient. He has lectured in North America, Europe,
Middle East, Asia, and Latin America on issues related to cleaning and disinfection
and microbial control in cleanrooms. Mr. Polarine is a frequent industry speaker
and published several PDA book chapters and articles related to cleaning and disinfection and
contamination control. He is active as co-chair on the PDA’s microbial investigations task force. He
was a co-author on PDA’s Technical Report #70 on Cleaning and Disinfection. Mr. Polarine teaches
the cleaning and disinfection course at the PDA Aseptic Processing Course and at the University
of Tennessee’s Parenteral Medications Course. Mr. Polarine is currently President Elect for the PDA
Missouri Valley and Technical Coordinator for the IEST. Mr. Polarine graduated from the University of
Illinois with a Master of Arts in Biology. He previously worked as a clinical research coordinator with
the Department of Veterans Affairs in St. Louis, MO and as a biology and microbiology instructor
at the University of Illinois. His main hobby is storm chasing and is very active in tornado research
and tornado safety.
Agenda
8.20 Registration Coffee
8.30 Opening remarks and introductions
9.00 A Risk based Cleaning and Disinfection Program
• Cleaning and Disinfection Methods and
Frequencies
• Disinfectant Rotation
• Rinsing and Residue Removal Frequencies
9.35 bringing the Cleanroom Online After a Worst-
Case Event
• Cleaning Steps Cleanroom Control
• Triple Cleaning Methods and Case Study
• Cleanroom Utilities and Operations Online
10.10 Coffee break
10.30 Disinfectant validation
• Requirements for Manufacturers
• Requirements for Pharmaceutical, biotech,
and Medical Device industries
• Case Studies in Disinfectant validation
11.05 Continuation of Disinfectant validation and
Contamination Control Case Studies
• Overview of Disinfectant validation
• Case Studies in Contamination Control
• Methods to Proactively Prevent bioburden
from Entering Cleanrooms
11.40 Closing remarks
12.00 lunch
C: Rapid Micro Methods, Endotoxin Testing and lER 15.40 - 18.40
Workshop leaders:
Felix Alejandro Montero Julian, Scientifi c Director, bioMerieux
Stefane Schweicher, Business Development Manager Endotoxin NEC, bioMerieux
Workshop overview:
The control of objectionable microorganisms and endotoxins in pharmaceutical products is vital to
ensure the complete safety from diverse immune reactions associated with exposure. As products
become more complex, rapid micro methods and alternative endotoxin testing and LER become
more routine and signifi cant, which suggests continuous assessment and validation. This workshop
will start with a revision of the current regulatory landscape set by the authorities such as FDA and
EMA. Following this will be an examination of the most robust RMMs, the pros and cons associated,
and prescribed implementation and validation strategies. The 2nd half of the workshop will survey
and compare routine endotoxin testing methods with proposed alternatives. The workshop fi nishes
off with an expert view of how to address LER and a means of evaluating contamination risk.
About the Workshop leaders:
Felix is a Scientifi c Director of the Healthcare Business of bioMerieux. Felix has over
25 years of experience in industrial and clinical diagnostics and previously served as
the Chemunex RD Director in bioMerieux. Felix graduated from the Autonomous
Metropolitan University in Mexico as Industrial Biochemistry Engineer and obtained a
PhD in Immunology from the Aix Marseille II University in France. Felix is a member of
different scientifi c organizations (PDA, ISAC) and served as an expert in a panel for
the Development of Compendial Rapid Sterility Tests for the USP. Felix has been and continues
to be extensively involved in the implementation and acceptance of rapid and alternative
microbiological methods. He is a prominent speaker at congresses and conferences and a
regular contributor to bioMerieux whitepapers.
Stéphane got a inter university degree in Cytometry and universities of Grenoble Reims. He worked for 10 years at various spin-off, biotech, CMO many
in the fi eld of cancer immunotherapy. Before moving to sales as account manager for endotoxin (Lonza) and after in the fi eld of lab automation (Tecan).
Stephane joined bioMérieux as Business development manager endotoxin in Jan 2019 for the Northern European Countries.
Agenda
15.40 Registration and Coffee
16.00 Update on RMM Regulation
• Regulatory Framework
16.35 Evaluating and validating the best RMM
Application based on Your Needs
• Technologies
• validation strategy
• implementation
17.10 Afternoon Tea
17.30 Endotoxin Detection
• Regulation: what is new?
• fFc testing
• validation
18.05 lER
• What is lER?
• PDA Technical Report 82
18.40 Closing remarks
iNTERACTivE POST CONFERENCE WORKSHOP DAY
WEDNESDAY 22ND JANUARY 2020 | COPTHORNE TARA HOTEl, lONDON, UK

5. SPONSORSHiP AND EXHibiTiON OPPORTUNiTiES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime networking opportunities
exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing
number of companies benefiting from sponsoring our conferences please call: Alia Malick, Director on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
Specializing in chromogenic and turbidimetric reagent technologies, Associates of Cape Cod, inc. (ACC) has been a
leader in endotoxin and (13)-ß-D-glucans detection products and services for nearly 45 years. ACC pioneered LAL testing
methodology and was the fi rst FDA licensed company to manufacture LAL reagents.
www.acciusa.com/acc/index.html
bioMérieux, inc. Pioneering Diagnostics bioMérieux provides a wide range of solutions for microbiological control dedicated
to the pharmaceutical industry. bioMérieux provides solutions for in-process controls and fi nal product testing. From surface
and personnel monitoring to air sampling, microbial detection and identifi cation, bioMérieux helps the pharmaceutical
industries manage microbiological risks and achieve compliance.
www.biomerieux.com/en/industry-solutions
With a rightful reputation for innovation, COPAN is the world leading manufacturer of collection and transport systems.
In like manner, COPAN’s collaborative approach to pre-analytics has resulted in the development of FLOQSwabs®,
ESwab®, UTM® and modular laboratory automation, WASP® and WASPLab®. For further information on COPAN, visit
www.copangroup.com
METTlER TOlEDO Thornton has a long history of delivering real time, continuous measurement products specifi cally designed
for regulated pharmaceutical water systems such as Conductivity, TOC, and Ozone. The 7000RMS Real time Microbial
System instantly detects and counts microbial (bioburden) presence enabling increased sensitivity, better process control,
improved product quality, and reduced risk. www.mt.com
Microgenetics is a biotech company specialising in microbiology, with two products currently:
• SmartControl, allowing easy capture and analysis of microbiological environmental monitoring data and is
pre-validated for GMP compliance
• SwiftDetect, an ultra-sensitive rapid sterility test capable of detecting a single cell in a large sample volume in 6 hours
microgenetics.co.uk
Reading Scientific Services limited (RSSl) provides analytical, investigational, consultancy and training services to clients
in the global pharmaceutical, biopharmaceutical and healthcare industries. Our GMP compliant facilities are located
in the UK and with our team of more than 300 dedicated employees, we ensure that every project is performed with
our commitment to outstanding quality, scientifi c excellence and customer satisfaction. We offer a large portfolio of,
chemical, physical, biochemical and microbiological services providing support through the full drug product life cycle. Our
comprehensive range of services include: Microbial Limits testing (EP, BP, USP, CP and JP); Quantitative Endotoxin Analysis;
Preservative Effi cacy Testing; Environmental Monitoring ;Water Testing; Extractables and leachables studies; GMP Batch
Release ; Stability Studies; Method development and validation; Physical and Structural Characterisation; Contamination
identifi cation and troubleshooting; Regulatory and compliance training; Consultancy. www.rssl.com
veltek Associates, inc. (vAi) is an EPA/FDA registered manufacturing facility, specialising in contamination control. Our
range of sterile disinfectants, sporicides, wipes and process cleaning detergents, complement our sterile, disposable
cleanroom garments which offer comfortable, breathable garments with outstanding particulate performance. Along with
our environmental air sampling equipment to determine levels of contamination present in the air, Veltek is committed to
providing our customers with the highest quality products. https://sterile.com
PROUDlY SPONSORED bY:
Register online at www.pharma-microbiology.com
MARKETiNg PARTNERSHiP OPPORTUNiTiES
Want to know how you can get involved? interested in promoting your services to this market?
Contact Simi Sapal, Marketing Manager on +44(0)207 827 6162 or email: ssapal@smi-online.co.uk
OFFiCiAl MEDiA PARTNERS SUPPORTiNg MEDiA PARTNERS
JOb TiTlE bREAKDOWN
9%
Head/Chief
24%
Microbiologist
45%
Project Manager
15%
Director
7%
Founder/
President/
CEO
COMPANY bREAKDOWN
82%
Pharma
18%
Industry Solution
Providers
155+Microbilogisiut and Industry
Professionals from US,
Europe and Asia
10+Dedicated hours
of networking
NETWORKiNg ATTENDEE gEOgRAPHY
iNFOgRAPHiCS 2019Pharmaceutical
Microbiology Series
SAvE THE DATE
Pharmaceutical
Manufacturing
Cleanroom Technology
9th - 10th October 2019
London, UK
Pharmaceutical
Microbiology East Coast
29th - 30th April 2020
Boston, USA
Pharmaceutical
Microbiology West Coast
18th - 19th June 2020
San Diego, USA
62% UK
8% USA
1% Canada
6% Switzerland
6% France
4% Germany
2% Denmark
2% Netherland
2% Belgium
7% Rest of Europe

6. Pharmaceutical Microbiology UK 2020
Conference: 20th – 21st January 2020, Copthorne Tara Hotel, London, UK Workshops: 22nd January 2020, Copthorne Tara Hotel, London, UK
4 WAYS TO REGISTER
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
Online at www.pharma-microbiology.com
POST your booking form to: Events Team, SMi Group Ltd,
Ground Floor, India House, 45 Curlew Street, London SE1 2ND
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk
Unique Reference Number
Our Reference P-307
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-307 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
SMi Group will apply surcharges to commercial cards
Please tick here □ if the card provided is not a commercial card
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
Documentation
I cannot attend but would like to Purchase access to the following Document Portal/
Paper Copy documentation. Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
PAYMENT
vat
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged
on Document portal and literature distribution for all UK customers and for those EU
Customers not supplying a registration number for their own country here
CONFERENCE Prices GROUP DISCOUNTS AVAILABLE
I would like to attend: (Please tick as appropriate) Fee TOTAL
□ Conference Workshop Day £2398.00 + VAT £2877.60
□ Conference only £1499.00 + VAT £1798.80
□ Workshop Focus day £899.00 +VAT £1078.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to
the Document Portal. Presentations that are available for download will be subject
to distribution rights by speakers. Please note that some presentations November not
be available for download. Access information for the document portal will be sent
to the e-mail address provided during registration. Details are sent within 24 hours post
conference.
□ Book by 30th September to receive £400 off the conference price
□ Book by by 31st October to receive £200 off the conference price
□ Book by 29th November to receive £100 off the conference price
EARLY BIRD
DISCOUNT
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
If you would like to continue to receive email updates about our
events, please tick □
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid
immediately and prior to the start of the event. If payment has not been received then credit card details will
be requested and payment taken before entry to the event. Bookings within 7 days of event require payment
on booking. Access to the Document Portal will not be given until payment has been received.
Substitutions/Name Changes: If you are unable to attend you November nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates Novembernot
‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation:Ifyouwishtocancelyourattendanceataneventandyouareunabletosendasubstitute,then
we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made
in writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this time
cannot be accepted. We will however provide the conferences documentation via the Document Portal to
anydelegatewhohaspaidbutisunabletoattendforanyreason.DuetotheinteractivenatureoftheBriefings
wearenotnormallyabletoprovidedocumentationinthesecircumstances.Wecannotacceptcancellations
of orders placed for Documentation or the Document Portal as these are reproduced specifically to order.
If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any
further liability.
Alterations: It November become necessary for us to make alterations to the content, speakers, timing,venue
or date of the event compared to the advertised programme.
Privacy policy / Opt Out: For full details on our privacy policy please go to
http://smi-online.co.uk/privacy-legals/privacy-policy. If you no longer wish to receive email
updates you can opt out by going to the following webpage http://www.smi-online.co.uk/opt-out
Terms and Conditions of Booking
Delegate Details
venue Copthorne Tara Hotel, London, UK
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712